Vectura’s VR475 asthma drug-device fails to meet primary endpoint in phase III study

Image: Vectura’s VR475 asthma drug-device has failed to meet primary endpoint in phase III study. Photo: courtesy of David Castillo Dominici / FreeDigitalPhotos.net.